Evaluation of sCD14 and sCD163 in vaccinated subjects with Pfizer-BioNTech (BNT162b2) or Sinopharm (BBIBP-CorV) COVID-19 vaccine in Iraq

• Main Authors: Bohan, Azhar Jabbar, Alubadi, Alia Essam Mahmood, Khalaf, Hind Yousif, Basheer, Nada Nadhir
• Format: Conference Proceeding
• Language: English
• Subjects: Coronaviruses; COVID-19 vaccines; Macrophages; Vaccines; Viral diseases
• ISSN: 0094-243X; 1551-7616
• DOI: 10.1063/5.0209763

After the wide spread of the Coronavirus in the world, which infected many people and claimed the lives of some of them, it was necessary to take quick preventive measures to limit its spread, so work was authorized using many new vaccines, including Pfizer-BioNTech (BNT162b2) and Sinopharm (BBIBP-CorV) vaccines, which witnessed widespread use in several countries, including Iraq, Therefore, this study was conducted to determine the sCD14 and sCD163 concentrations by using the diagnostic kit represented by the sandwich ELISA kit, manufactured by Elabscience Company, in the serum of vaccinated subjects with Pfizer-BioNTech (BNT162b2) or Sinopharm (BBIBP-CorV) vaccine, infected patients and recovered patients with covid-19, and the results of sCD14 concentration showed significant differences in subjects after the second dose of two vaccines, convalescent patients and infected patients, and there was no significant difference between the infected and convalescent patients, while the sCD163 concentration doesn’t show any significant differences in subjects after the second dose of two vaccines and convalescent patients and infected patients also, there was no significant difference between the infected and convalescent patients and also When comparing the two vaccines for sCD14 and sCD163 after the second dose, therefore, This study concludes that the two vaccines, Pfizer-BioNTech (BNT162b2) and Sinopharm (BBIBP-CorV), had no role in stimulating mono-cytes/macrophages in terms of sCD14 and sCD163 levels, as happens during SARS-CoV-2 infection consequences and after recovery from it.